Erika Girardi's Avatar

Erika Girardi

@alphaerika

Associate professor at University of Strasbourg. Molecular biologist interested in viruses, RNA and innate immunity 🧬🦠

1,123
Followers
466
Following
8
Posts
11.11.2024
Joined
Posts Following

Latest posts by Erika Girardi @alphaerika

Thank you Annemarthe for having accepted to be part of the jury !

17.09.2025 12:15 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0
Photo of Charline and her jury members after the defense

Photo of Charline and her jury members after the defense

Today was a great day for Charline Pasquier, who successfully defended her PhD thesis in front of the jury composed of @annemarthe.bsky.social @ericci-aeruginosa.bsky.social, Stefania Millevoi and Jean-Luc Imler. Congratulations to her for a brilliant defense! 🍾

16.09.2025 17:25 πŸ‘ 12 πŸ” 1 πŸ’¬ 1 πŸ“Œ 1
Post image

#InterferonPower! Thrilled for our latest work @cp-cell.bsky.social! With @danielboehmer.bsky.social, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IVπŸ˜‰) #interferons! FreeπŸ‘‰ authors.elsevier.com/a/1leKGL7PXu...

21.08.2025 15:20 πŸ‘ 78 πŸ” 34 πŸ’¬ 1 πŸ“Œ 4

@sebpfeffer.bsky.social , @agencerecherche.bsky.social , @unistra.fr

18.07.2025 20:39 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0
Preview
Fatty Acid Synthase binds endogenous dsRNAs and dampens the innate immune response to exogenous dsRNAs by limiting their accumulation. In mammalian cells, the presence of double-stranded RNA (dsRNA) in the cytoplasm is a danger signal indicative of viral infection. Cells establish and maintain an antiviral state via the production of...

I am happy to share our last preprint, where we identified FASN as an endogenous dsRNA-associated factor and demonstrated that its depletion triggers endodsRNA accumulation and a stronger antiviral response to exogenous dsRNAs,#RNA, #interferon,#immunometabolism
www.biorxiv.org/cgi/content/...

18.07.2025 20:37 πŸ‘ 16 πŸ” 7 πŸ’¬ 1 πŸ“Œ 0
Preview
First Patient Treated with Personalized CRISPR Therapy, Developed in Just Six Months The first on-demand CRISPR therapy for an infant with a rare metabolic disease developed by the IGI and collaborators around the world.

This is what can be achieved today due to longstanding federal support of academic basic science alongside close partnership of universities, private industry and NIH intramural initiatives. An ecosystem worth not just saving but doubling down on!

innovativegenomics.org/news/first-p...

15.05.2025 17:40 πŸ‘ 232 πŸ” 85 πŸ’¬ 3 πŸ“Œ 5

So honored and happy to share that I was awarded the 2024 Guy Ourisson Prize. A big thank you to my mentors, colleagues, and students, past and present, without whom it would have never been possible!

14.05.2025 10:47 πŸ‘ 3 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

πŸ™‹πŸ»β€β™€οΈplease

20.11.2024 18:43 πŸ‘ 1 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

πŸ™‹πŸ»β€β™€οΈplease

18.11.2024 22:08 πŸ‘ 0 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0

πŸ™‹πŸ»β€β™€οΈ

17.11.2024 18:19 πŸ‘ 1 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

πŸ™‹πŸ»β€β™€οΈ

17.11.2024 17:13 πŸ‘ 1 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0